CDT Equity Inc., a clinical-stage pharmaceutical developer focusing on AI-enhanced asset repositioning and solid-form chemistry to extend drug patent life, reported a critical cash depletion to $97,000 as of March 2026, raising substantial doubt about its ability to continue as a going concern. The company leverages strategic partnerships, including exclusive licenses with AstraZeneca and a technological collaboration with Sarborg Limited, to accelerate development and licensing of deprioritized Phase I compounds. Despite operational advances in its autoimmune, rare disease, and veterinary asset pipeline, CDT's capital efficiency remains under threat by mounting accrued litigation liabilities and low current assets relative to liabilities. Monitoring milestone acquisitions, licensing deals, and capital raises will be key to evaluating CDT’s path forward.